Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of cimlanod (BMS-986231) in hospitalized patients with heart failure and impaired systolic function
jRCT2080224035Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2018
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of cimlanod in heart failure (HF) and heart failure with reduced ejection fraction (HFrEF) (4 arms), sponsored by Bristol Myers Squibb. Started Sep 2018; status: completed.
02
Drugs
cimlanod
03
Conditions
heart failure (HF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on jRCT2080224035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224035.